Dr. Luc Vallières is a Professor in the Department of Molecular Medicine at Laval University and a neuroimmunology researcher in the Neuroscience Unit at the CHU de Québec.

He began his career in 2002 after a postdoctoral training at the Salk Institute in California in the field of postnatal neurogenesis (1998-2001). This training was preceded by a doctorate in physiology at Laval University (1993-1998) and a bachelor’s degree in biology at the Université du Québec à Chicoutimi (1990-1993).

He is studying two diseases that afflict the central nervous system: multiple sclerosis and brain cancer. His research program aims to better understand how immune cells are regulated in these diseases in the hope of finding a way to neutralize or stimulate them for therapeutic purposes. This program is well funded by the CIHR, NSERC and Multiple Sclerosis Society of Canada.

He has made a significant contribution to the field of neuroimmunology by discovering a population of immune cells that constantly patrols the blood vessels of the nervous system and by elucidating mechanisms that govern their recruitment and functions under inflammatory conditions.

His research led to an international patent claiming the first ever drug that would specifically calm the neutrophil, an immune cell normally beneficial, but that can be involved in many inflammatory diseases.

His technical background includes single cell-RNA sequencing, STED super-resolution microscopy, flow cytometry, CRISPR-Cas9 gene editing and RNA interference, as well as bone marrow transplantation. Strong of this expertise, he directs the super-resolution microscopy and irradiation platforms at the CHU de Québec.

He is responsible of two courses, namely Principles of Neuroimmunology (MMO-7010) and Current Techniques in Molecular Medicine (MMO-7019).

Among his external activities, he is chairing the organizing committee of the 16th Congress of the International Society of Neuroimmunology, which will take place in Quebec City in August 2022. He is associate editor of the journal Mediators of Inflammation. He also serves on neuroscience committees at the CIHR.

CHUL
2705, boulevard Laurier
T-2-50
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

33 entries « 2 of 4 »

Perez CJ, Dumas A, Vallieres L, Guenet JL, Benavides F

Several classical mouse inbred strains, including DBA/2, NOD/Lt, FVB/N, and SJL/J, carry a putative loss-of-function allele of Gpr84.

Journal Article

J Hered, 104 (4), pp. 565-71, 2013, ISSN: 0022-1503.

Abstract | Links:

Ramesh G, Philipp MT, Vallieres L, Maclean AG, Ahmad M

Mediators of neuroinflammation.

Journal Article

Mediators Inflamm, 2013 , pp. 314261, 2013, ISSN: 0962-9351.

| Links:

Santiquet N, Vallieres L, Pothier F, Sirard MA, Robert C, Richard F

Transplanted bone marrow cells do not provide new oocytes but rescue fertility in female mice following treatment with chemotherapeutic agents.

Journal Article

Cell Reprogram, 14 (2), pp. 123-9, 2012.

Abstract | Links:

Roy M, Richard JF, Dumas A, Vallieres L

CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis.

Journal Article

J Neuroinflammation, 9 , pp. 18, 2012.

Abstract | Links:

Richard JF, Roy M, Audoy-Remus J, Tremblay P, Vallieres L

Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1 and ITGαM.

Journal Article

Brain Pathol, 21 (6), pp. 661-71, 2011, ISSN: 1015-6305.

Abstract | Links:

Tremblay P, Beaudet MJ, Tremblay E, Rueda N, Thomas T, Vallieres L

Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair.

Journal Article

J Pathol, 224 (2), pp. 222-33, 2011, ISSN: 0022-3417.

Abstract | Links:

Beaudet MJ, Rueda N, Kobinger GP, Villeneuve J, Vallieres L

Construction of a ganciclovir-sensitive lentiviral vector to assess the influence of angiopoietin-3 and soluble Tie2 on glioma growth.

Journal Article

J Neurooncol, 99 (1), pp. 1-11, 2010, ISSN: 0167-594X.

Abstract | Links:

Vallieres L

Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.

Journal Article

IDrugs, 12 (7), pp. 445-53, 2009, ISSN: 1369-7056.

Abstract | Links:

Audoy-Remus J, Richard JF, Soulet D, Zhou H, Kubes P, Vallieres L

Rod-Shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2.

Journal Article

J Neurosci, 28 (41), pp. 10187-99, 2008, ISSN: 0270-6474.

Abstract | Links:

Villeneuve J, Galarneau H, Beaudet MJ, Tremblay P, Chernomoretz A, Vallieres L

Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment.

Journal Article

Brain Pathol, 18 (3), pp. 401-14, 2008, ISSN: 1015-6305.

Abstract | Links:

33 entries « 2 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
  • Characterization of a novel dendritic cell-specific protein in demyelinating autoimmune diseases, Subvention, Société canadienne de la sclérose en plaques, from 2019-04-01 to 2022-03-31
  • Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31
  • Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, Subvention, Société canadienne de la sclérose en plaques, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2018-04-30
  • Mécanisme d’immunomodulation par le GPR84, un récepteur d’acides gras., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2015-04-01 to 2020-03-31
  • Role of neutrophils as antigen-presenting cells in autoimmune demyelination, Subvention, Société canadienne de la sclérose en plaques, Subvention de fonctionnement, from 2016-04-01 to 2019-03-31
Data provided by the Université Laval research projects registery